Patents by Inventor Henry Perry Fell, Jr.

Henry Perry Fell, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for augmenting an immune response using anti-CD40 antibodies
    Patent number: 7824683
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: December 28, 2009
    Date of Patent: November 2, 2010
    Assignee: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
  • METHODS FOR AUGMENTING AN IMMUNE RESPONSE USING ANTI-CD40 ANTIBODIES
    Publication number: 20100158906
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Application
    Filed: December 28, 2009
    Publication date: June 24, 2010
    Applicant: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, JR.
  • Methods for the treatment of cancer using anti-CD40 antibodies
    Patent number: 7666422
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: January 20, 2009
    Date of Patent: February 23, 2010
    Assignee: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
  • METHODS FOR THE TREATMENT OR PREVENTION OF IMMUNE DISORDERS USING ANTI-CD40 ANTIBODIES
    Publication number: 20090280117
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Application
    Filed: January 20, 2009
    Publication date: November 12, 2009
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, JR.
  • Methods for the treatment of cancer using anti-CD40 antibodies
    Patent number: 7510711
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: March 31, 2009
    Assignee: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
  • Methods for treating immune disorders or cancer with anti-CD40 antibodies
    Patent number: 7498032
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: March 3, 2009
    Assignee: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
  • Recombinant anti-CD40 antibody and uses thereof
    Patent number: 6946129
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: June 8, 1999
    Date of Patent: September 20, 2005
    Assignee: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
  • Methods for the treatment and prevention of cancer using anti-CD40 antibodies
    Patent number: 6843989
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 18, 2005
    Assignee: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
  • Nucleic acids encoding anti-CD40 proteins and methods of producing recombinant anti-CD40 proteins
    Patent number: 6838261
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 4, 2005
    Assignee: Seattle Genetics, Inc.
    Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
  • Therapeutic antibody based fusion proteins
    Patent number: 5645835
    Abstract: The present invention relates to methods of providing a targeted, amplified antitumor immune response using antibody-based fusion proteins. More specifically, the invention relates to the use of antibody-based fusion proteins comprising an immunoglobulin portion capable of binding to a tumor antigen linked to a biologically active lymphokine. The immunoglobulin portion targets the fusion protein to the site of the tumor cells and the lymphokine portion stimulates the proliferation of immune T cells at the site of the tumor cells, thereby amplifying the anti-tumor immune response. In preferred embodiments of the invention, the immunoglobulin portion of the fusion protein is derived from the L6 monoclonal antibody and/or the lymphokine is interleukin-2.
    Type: Grant
    Filed: May 23, 1994
    Date of Patent: July 8, 1997
    Assignee: Oncogen
    Inventors: Henry Perry Fell, Jr., Margit Ann Gayle